13th August 2024
Last month, BioM, the renowned biotechnology cluster organisation in Munich and Bavaria, joined EIT Health Germany-Switzerland as a Network Partner. This strategic partnership aims to foster innovation, growth, and value creation in the fields of medicine and biotechnology.
Founded over 25 years ago, BioM has established itself as a cornerstone of Bavaria’s biotech landscape. As a non-profit organisation operating under the auspices of the Bavarian Ministry of Economic Affairs, BioM creates a unique ecosystem for innovation, growth, and value creation in medicine and biotechnology. Their mission is to connect relevant partners and support Bavarian biotech companies, from startups to established enterprises.
BioM offers extensive support for emerging entrepreneurs through comprehensive advisory services and specialised coaching, training, and mentoring programmes. Their MAxL incubator (Munich Accelerator Life Sciences & Medicine) provides optimal conditions for pre-seed projects and early-stage startups in the biotech and healthtech sectors. Additionally, since 2011, BioM has been coordinating the m4 Award, a pre-seed competition in biomedicine, funded by the Bavarian Ministry of Economic Affairs with a total of €2.5 million every second year. BioM has already supported over 250 startups through these initiatives.
Prof. Dr. Ralf Huss, Managing Director of BioM, expressed his enthusiasm for the new partnership: “Joining EIT Health Germany-Switzerland allows us to extend our reach and collaborate with an even broader network of health innovators. We are excited about the potential synergies and the opportunity to contribute to advancing healthcare solutions across Europe.”
Dr. Astrid Kaltenböck, Managing Director of EIT Health Germany-Switzerland, also welcomed BioM to the community, stating: “BioM’s dedication to fostering innovation in biotechnology aligns perfectly with our mission. We look forward to a fruitful collaboration and supporting BioM in their efforts to drive advancements in healthcare.”
The Bavarian Biotech Cluster, coordinated by BioM, includes over 520 biotechnology and pharmaceutical companies, as well as associated service providers. The region’s core competencies lie in developing innovative therapeutics, diagnostics, and underlying technologies, particularly for personalised medicine.
For more information about BioM and their initiatives, visit their website here.
Corify Care raises €6M to revolutionise cardiac care
A significant milestone for the company.
Luminate Medical secures additional $2.5M to advance cancer care
A significant milestone for the company.
Longenesis teams up with Novartis for digital heart care innovation
Pilot project for treatment of cardiovascular diseases.